Can atomoxetine (Strattera) be taken together with bupropion extended‑release (Wellbutrin XL)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 17, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Can Strattera and Wellbutrin XL Be Taken Together?

Yes, atomoxetine (Strattera) and bupropion extended-release (Wellbutrin XL) can be taken together, but this combination requires careful monitoring due to a significant pharmacokinetic drug interaction that increases atomoxetine exposure approximately 5-fold.

Key Drug Interaction

Bupropion inhibits CYP2D6, the primary enzyme responsible for metabolizing atomoxetine. Research demonstrates that bupropion pretreatment increases atomoxetine AUC by 5.1-fold (from 1580 to 8060 ng*h/mL) and Cmax by 1.7-fold, while simultaneously decreasing the main metabolite exposure by 1.5-fold 1. This interaction essentially converts extensive CYP2D6 metabolizers into poor metabolizers pharmacokinetically.

Clinical Management Strategy

Dosing Adjustments Required

When combining these medications:

  • Start atomoxetine at reduced doses (approximately 40 mg daily in adults, adjusted every 7-14 days to 60-80 mg maximum, rather than the typical 1.4 mg/kg/day or 100 mg/day) 2
  • Treat the patient as a CYP2D6 poor metabolizer for dosing purposes, as bupropion creates this phenotype pharmacologically
  • Monitor closely for atomoxetine-related adverse effects including cardiovascular changes (increased heart rate and blood pressure), gastrointestinal symptoms, initial somnolence, and decreased appetite 3

When This Combination Makes Sense

This combination is most appropriate for:

  • Patients with ADHD and comorbid depression requiring treatment for both conditions 4
  • Patients who have inadequate response to stimulant monotherapy and need augmentation with a non-stimulant 5
  • Patients switching from stimulants to non-stimulant options where bupropion offers advantages for co-occurring depression 4

Note that bupropion is less efficacious than stimulants for ADHD core symptoms 4, so this combination typically serves patients with specific comorbidity profiles rather than as first-line ADHD treatment.

Safety Monitoring

Cardiovascular Surveillance

  • Obtain personal and family cardiac history before initiating either medication
  • Monitor heart rate and blood pressure regularly, as atomoxetine increases these parameters while bupropion can also affect cardiovascular function 3
  • Consider baseline ECG if cardiac risk factors are present

Neuropsychiatric Monitoring

  • Both medications carry warnings about mood changes and suicidal ideation 6, 2
  • Atomoxetine has an FDA black box warning for increased suicidal thoughts
  • Bupropion carries warnings about neuropsychiatric effects, depression, and mania 7
  • Monitor closely for emergence of agitation, hostility, depression, or suicidal ideation, especially during initiation and dose adjustments

Seizure Risk Considerations

Bupropion lowers the seizure threshold (0.1% seizure risk) 7, 8. This combination should be avoided or used with extreme caution in patients with:

  • History of seizures or seizure disorders
  • Brain metastases or elevated seizure risk
  • Eating disorders (bulimia, anorexia nervosa) - absolute contraindication for bupropion 8
  • Abrupt discontinuation of alcohol or benzodiazepines - contraindication for bupropion 8

Important Contraindications and Warnings

Bupropion Contraindications

  • Seizure disorders
  • Current or prior bulimia or anorexia nervosa
  • Abrupt discontinuation of alcohol or sedatives
  • Concurrent MAOI use (14-day washout required)
  • Concurrent use with other bupropion-containing products (Zyban, Wellbutrin SR, Wellbutrin IR) 8

Drug-Drug Interaction Concerns

Bupropion should not be combined with MAOIs due to hypertensive crisis risk 6. The combination of atomoxetine and bupropion with other psychotropic medications requires careful evaluation, particularly with:

  • SSRIs or SNRIs (which may further inhibit CYP2D6)
  • Other medications metabolized by CYP2D6
  • Medications that lower seizure threshold

Evidence Quality and Guideline Support

While older ADHD guidelines from 2002 note that "there are no studies of the combination of bupropion and stimulants" and recommend proceeding "with caution in combining these agents" 9, this guidance predates the specific atomoxetine-bupropion interaction study. The 2016 pharmacokinetic study provides clear evidence of the magnitude of this interaction 1.

More recent guidelines (2024) specifically mention switching from stimulants to bupropion in the perinatal period for patients requiring treatment of co-occurring depression, acknowledging bupropion's established safety profile in pregnancy while noting it is "not as efficacious as stimulants for the treatment of ADHD" 4.

Clinical Bottom Line

This combination can be used safely with appropriate dose reduction of atomoxetine (treating as CYP2D6 poor metabolizer) and vigilant monitoring for cardiovascular effects, neuropsychiatric symptoms, and seizure risk. The primary indication is ADHD with comorbid depression where both conditions require pharmacological treatment. Alternative strategies should be considered in patients with seizure disorders, eating disorders, or multiple psychotropic medication requirements.

References

Research

Evaluation of a Potential Metabolism-Mediated Drug-Drug Interaction Between Atomoxetine and Bupropion in Healthy Volunteers.

Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques, 2016

Guideline

attention-deficit/hyperactivity disorder in pregnancy and the postpartum period.

American Journal of Obstetrics and Gynecology, 2024

Guideline

american association of clinical endocrinologists and american college of endocrinology comprehensive clinical practice guidelines for medical care of patients with obesity.

Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologist, 2016

Guideline

smoking cessation, version 1.2016, nccn clinical practice guidelines in oncology.

Journal of the National Comprehensive Cancer Network : JNCCN, 2016

Guideline

practice parameter for the use of stimulant medications in the treatment of children, adolescents, and adults.

Journal of the American Academy of Child and Adolescent Psychiatry, 2002

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.